Clinical Trial

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Study acronym: Enith1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity.
Protocol Amendment History 6 changes
notable Trial sites expanded: 128 -> 164 locations 2026-07-21
notable Trial sites expanded: 73 -> 128 locations 2026-06-24
notable Trial sites expanded: 58 -> 73 locations 2026-06-02
notable Trial sites expanded: 28 -> 58 locations 2026-05-27
notable Trial sites expanded: 22 -> 28 locations 2026-04-25
notable Trial sites expanded: 2 -> 22 locations 2026-04-08
Trial Details
NCT Number NCT07351045
Lead Sponsor Hoffmann-La Roche
Conditions Obesity or Overweight
Enrollment 2,000 participants
Start Date 2026-03-16
Primary Completion 2028-07-24 (estimated)
Study Completion 2028-08-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-20